Abstract:Importance Although the risk of parvovirus B19 infection during pregnancy and subsequent risk of adverse fetal outcome are low, understanding management practices is essential for proper treatment of fetuses with nonimmune hydrops fetalis. In addition, continued investigation into delivery management, breastfeeding recommendations, and congenital abnormalities associated with pregnancies complicated by parvovirus B19 infection is needed. Objective This review describes the risks associated with parvovirus B19 infection during pregnancy and the management strategies for fetuses with vertically transmitted infections. Evidence Acquisition Original articles were obtained from literature search in PubMed, Medline, and OVID; pertinent articles were reviewed. Results Parvovirus B19 is a viral infection associated with negative pregnancy outcomes. Up to 50% of people of reproductive age are susceptible to the virus. The incidence of B19 in pregnancy is between 0.61% and 1.24%, and, overall, there is 30% risk of vertical transmission when infection is acquired during pregnancy. Although most pregnancies progress without negative outcomes, viral infection of the fetus may result in severe anemia, congestive heart failure, and hydrops fetalis. In addition, vertical transmission carries a 5% to 10% chance of fetal loss. In pregnancies affected by fetal B19 infection, Doppler examination of the middle cerebral artery peak systolic velocity should be initiated to surveil for fetal anemia. In the case of severe fetal anemia, standard fetal therapy involves an intrauterine transfusion of red blood cells with the goal of raising hematocrit levels to approximately 40% to 50% of total blood volume. One transfusion is usually sufficient, although continued surveillance may indicate the need for subsequent transfusions. There are fewer epidemiologic data concerning neonatal risks of congenital parvovirus, although case reports have shown that fetuses with severe anemia in utero may have persistent anemia, thrombocytopenia, and edema in the neonatal period. Conclusions and Relevance Parvovirus B19 is a common virus; seropositivity in the geriatric population reportedly reaches 85%. Within the pregnant population, up to 50% of patients have not previously been exposed to the virus and consequently lack protective immunity. Concern for parvovirus B19 infection in pregnancy largely surrounds the consequences of vertical transmission of the virus to the fetus. Should vertical transmission occur, the overall risk of fetal loss is between 5% and 10%. Thus, understanding the incidence, risks, and management strategies of pregnancies complicated by parvovirus B19 is essential to optimizing care and outcomes. Further, there is currently a gap in evidence regarding delivery management, breastfeeding recommendations, and the risks of congenital abnormalities in pregnancies complicated by parvovirus B19. Additional investigations into optimal delivery management, feeding plans, and recommended neonatal surveillance are needed in this cohort of patients. Target Audience Obstetricians and gynecologists, family physicians Learning Objectives After completing this activity, the learner will be better able to discuss the incidence of parvovirus B19 in both the general and pregnant population as well as the risks associated with parvovirus B19 infection during pregnancy; explain current management standards for pregnancies complicated by parvovirus B19; and describe the gaps in knowledge regarding risk of congenital abnormalities, delivery recommendations, and breastfeeding practices for patients with pregnancies complicated by parvovirus B19.

Notes from the Field: Human Parvovirus B19 Infections Among Pregnant Persons — Minnesota, January–September 2024

Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024

The Relation Between the Parvovirus B19 and Pregnancy

Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19

Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic

Parvovirus B19 in Pregnancy

Detection of Increased Activity of Human Parvovirus B19 Using Commercial Laboratory Testing of Clinical Samples and Source Plasma Donor Pools — United States, 2024

Notes from the Field: Increase in Diagnoses of Human Parvovirus B19–Associated Aplastic Crises in Children and Adolescents with Sickle Cell Disease — Atlanta, Georgia, December 14, 2023–September 30, 2024

Parvovirus B19 remains an underestimated pathogen among infections during gestation in Argentina: Insights through the study of symptomatic and asymptomatic pregnant patients and newborns from Córdoba

An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024

EP04.05: Impact of the COVID‐19 pandemic on parvovirus B19 infection rates in pregnancy: is there a post‐pandemic epidemic?

Parvovirus B19 infection during pregnancy and risks to the fetus

Parvovirus B19 Outbreak in Israel: Retrospective Molecular Analysis from 2010 to 2023

Molecular-genetic characterization of human parvovirus B19 prevalent in Kerala State, India

Notes from the Field: Expanded Laboratory Testing for Varicella — Minnesota, 2016–2023

Seroepidemiology of Human Parvovirus B19 Infection among the Population of Vojvodina, Serbia, over a 16-Year Period (2008–2023)

Characteristics and outcomes of pregnant women hospitalized with laboratory-confirmed respiratory syncytial virus before and during the COVID-19 pandemic

Mild and asymptomatic influenza B virus infection among unvaccinated pregnant persons: Implication for effectiveness of non-pharmaceutical intervention and vaccination to prevent influenza

Neurological aspects of human parvovirus B19 infection: a systematic review

Molecular Testing for Parvoviruses